IFRX InflaRx NV: רווח למניה בשנים עשר החודשים האחרונים

Compliance with ESG standards and sustainable bio-waste accounting confirm the reliability of the credit profile. This 12-month net income per share chart demonstrates stability, with the metric holding around 0.00. The financial cushion is bolstered by the diversification of clinical trials in oncology and a high level of trust from the medical community in the targeted developments of InflaRx N.V. (IFRX).

InflaRx N.V. specializes in developing complement inhibitors for the therapy of severe inflammatory processes in intensive care units. The company's annual net profit per share reflects the final financial result allocated to a single common share over a rolling period. This metric neutralizes the impact of share issuance, allowing for an assessment of actual profit generation efficiency. Positive dynamics in annual net profit per share confirm the scalability of the business model. The current trend determines the issuer's fair market capitalization.